CN105008367B - 作为钾离子通道抑制剂的吡咯并三嗪类化合物 - Google Patents

作为钾离子通道抑制剂的吡咯并三嗪类化合物 Download PDF

Info

Publication number
CN105008367B
CN105008367B CN201480013619.4A CN201480013619A CN105008367B CN 105008367 B CN105008367 B CN 105008367B CN 201480013619 A CN201480013619 A CN 201480013619A CN 105008367 B CN105008367 B CN 105008367B
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
membered
phenyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480013619.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105008367A (zh
Inventor
H.芬莱
A.K.阿迪斯钱
N.K.洪迪
G.卡维塔
P.古纳加
J.罗伊德
P.斯里尼瓦苏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN105008367A publication Critical patent/CN105008367A/zh
Application granted granted Critical
Publication of CN105008367B publication Critical patent/CN105008367B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201480013619.4A 2013-03-11 2014-03-10 作为钾离子通道抑制剂的吡咯并三嗪类化合物 Expired - Fee Related CN105008367B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361775731P 2013-03-11 2013-03-11
US61/775731 2013-03-11
US14/200055 2014-03-07
US14/200,055 US9050345B2 (en) 2013-03-11 2014-03-07 Pyrrolotriazines as potassium ion channel inhibitors
PCT/US2014/022265 WO2014143610A1 (en) 2013-03-11 2014-03-10 Pyrrolotriazines as potassium ion channel inhibitors

Publications (2)

Publication Number Publication Date
CN105008367A CN105008367A (zh) 2015-10-28
CN105008367B true CN105008367B (zh) 2017-08-29

Family

ID=51488539

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480013619.4A Expired - Fee Related CN105008367B (zh) 2013-03-11 2014-03-10 作为钾离子通道抑制剂的吡咯并三嗪类化合物

Country Status (8)

Country Link
US (1) US9050345B2 (enExample)
EP (1) EP2970296B1 (enExample)
JP (1) JP6427551B2 (enExample)
CN (1) CN105008367B (enExample)
AR (1) AR095208A1 (enExample)
TW (1) TW201444847A (enExample)
UY (1) UY35381A (enExample)
WO (1) WO2014143610A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2858987T3 (pl) * 2012-06-11 2018-08-31 Bristol-Myers Squibb Company Proleki kwasu fosforoamidowego 5-[5-fenylo-4-(pirydyno-2-ylometylamino)chinazolino-2-ylo]pirydyno-3-sulfonamidu
US9458133B2 (en) 2013-03-11 2016-10-04 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
ES2616025T3 (es) 2013-03-11 2017-06-09 Bristol-Myers Squibb Company Pirrolotriazinas como inhibidores de canales de iones potasio
EP2970295B1 (en) 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolopyridazines as potassium ion channel inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP2018528951A (ja) * 2015-08-31 2018-10-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＴＧＦβ受容体アンタゴニスト
CN105111154A (zh) * 2015-09-15 2015-12-02 上海瑞博化学有限公司 一种5-氨基吡嗪-2-甲酸合成新工艺
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
PT3436461T (pt) 2016-03-28 2024-01-23 Incyte Corp Compostos de pirrolotriazina como inibidores de tam
DK3450436T3 (da) * 2016-04-28 2022-09-12 Takeda Pharmaceuticals Co Kondenseret heterocyklisk forbindelse
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
CN111825675B (zh) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
US20230416248A1 (en) * 2020-11-10 2023-12-28 Foghorn Therapeutics Inc. Compounds and uses thereof
CA3246424A1 (en) 2022-04-08 2023-10-12 SHY Therapeutics LLC Compounds interacting with proteins of the RAS superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP4522280A1 (en) 2022-05-11 2025-03-19 Foghorn Therapeutics Inc. Compounds and uses thereof
CN116063183B (zh) * 2023-01-28 2023-06-27 山东国邦药业有限公司 一种环丙胺的合成方法
WO2025077671A1 (zh) * 2023-10-09 2025-04-17 浙江海正药业股份有限公司 多取代芳基类衍生物及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071129A1 (en) * 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
WO2002040486A2 (en) * 2000-11-17 2002-05-23 Bristol-Myers Squibb Company METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS
WO2009026254A1 (en) * 2007-08-17 2009-02-26 Icagen, Inc. Heterocycles as potassium channel modulators
US20120232068A1 (en) * 2009-09-03 2012-09-13 Briston-Myers Squibb Company Quinazolines as potassium ion channel inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
KR20010083092A (ko) 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003265349A1 (en) 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
KR20050099525A (ko) 2003-02-05 2005-10-13 브리스톨-마이어스 스큅 컴퍼니 피롤로트리아진 키나제 억제제의 제조 방법
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
AU2005288858B2 (en) 2004-09-30 2011-04-21 Janssen R&D Ireland HCV inhibiting bi-cyclic pyrimidines
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
MX2008011136A (es) 2006-03-07 2008-09-08 Squibb Bristol Myers Co Compuestos de profamarco de pirrolotriazina anilina utiles como inhibidores de cinasa.
WO2007107005A1 (en) 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
PT2041138E (pt) 2006-07-07 2014-10-07 Bristol Myers Squibb Co Inibidores de pirrolotriazina quinase
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
WO2008131050A1 (en) 2007-04-18 2008-10-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
WO2009111531A1 (en) 2008-03-06 2009-09-11 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2010002472A1 (en) 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
JP5592890B2 (ja) * 2008-10-08 2014-09-17 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
PL2858987T3 (pl) * 2012-06-11 2018-08-31 Bristol-Myers Squibb Company Proleki kwasu fosforoamidowego 5-[5-fenylo-4-(pirydyno-2-ylometylamino)chinazolino-2-ylo]pirydyno-3-sulfonamidu

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071129A1 (en) * 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
CN1351498A (zh) * 1999-05-21 2002-05-29 布里斯托尔-迈尔斯斯奎布公司 激酶的吡咯并三嗪抑制剂
WO2002040486A2 (en) * 2000-11-17 2002-05-23 Bristol-Myers Squibb Company METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS
CN1622946A (zh) * 2000-11-17 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 治疗与p38激酶有关的症状的方法以及用作激酶抑制剂的吡咯并三嗪化合物
WO2009026254A1 (en) * 2007-08-17 2009-02-26 Icagen, Inc. Heterocycles as potassium channel modulators
CN101842011A (zh) * 2007-08-17 2010-09-22 安克进药物公司 作为钾通道调节剂的杂环
US20120232068A1 (en) * 2009-09-03 2012-09-13 Briston-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
CN102753535A (zh) * 2009-09-03 2012-10-24 百时美施贵宝公司 作为钾离子通道抑制剂的喹唑啉

Also Published As

Publication number Publication date
EP2970296B1 (en) 2016-12-21
US9050345B2 (en) 2015-06-09
TW201444847A (zh) 2014-12-01
JP2016512505A (ja) 2016-04-28
WO2014143610A1 (en) 2014-09-18
UY35381A (es) 2014-09-30
EP2970296A1 (en) 2016-01-20
AR095208A1 (es) 2015-09-30
US20140256719A1 (en) 2014-09-11
JP6427551B2 (ja) 2018-11-21
CN105008367A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
CN105008367B (zh) 作为钾离子通道抑制剂的吡咯并三嗪类化合物
KR101698631B1 (ko) 칼륨 이온 채널 억제제로서의 퀴나졸린
RU2720237C2 (ru) Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
AU2014248763B2 (en) Substituted piperidine compounds and their use as orexin receptor modulators
CN116554152A (zh) 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺
CN114466850B (zh) [1,2,4]三唑并[1,5-c]喹唑啉-5-胺
CN104781259A (zh) 抑制bet蛋白的5-芳基三唑并氮杂*
AU2019211382A1 (en) Aminopyrrolotriazines as kinase inhibitors
WO2023045960A1 (zh) 一种吡啶类衍生物及其用途
AU2018361249A1 (en) Aminoimidazopyridazines as kinase inhibitors
CA3082857A1 (en) 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
JP6386527B2 (ja) カリウムイオンチャネル阻害剤としてのピロロピリダジン
JP2016514129A (ja) カリウムイオンチャネル阻害剤としてのフタラジン
EP4429663A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists
JP2016516691A (ja) カリウムイオンチャネル阻害剤としてのイソキノリン
JP6395798B2 (ja) カリウムイオンチャネル阻害剤としてのピロロトリアジン
HK40074720B (zh) [1,2,4]三唑并[1,5-c]喹唑啉-5-胺
HK40074720A (en) [1,2,4]triazolo[1,5-c]quinazolin-5-amines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170829